1. Home
  2. TSAT vs LCTX Comparison

TSAT vs LCTX Comparison

Compare TSAT & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Telesat Corporation

TSAT

Telesat Corporation

HOLD

Current Price

$29.16

Market Cap

368.8M

Sector

Industrials

ML Signal

HOLD

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.66

Market Cap

407.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TSAT
LCTX
Founded
1969
1990
Country
Canada
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
368.8M
407.7M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
TSAT
LCTX
Price
$29.16
$1.66
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$4.25
AVG Volume (30 Days)
113.0K
1.2M
Earning Date
11-04-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$324,440,552.00
$10,816,000.00
Revenue This Year
N/A
$6.32
Revenue Next Year
N/A
$124.49
P/E Ratio
N/A
N/A
Revenue Growth
N/A
24.05
52 Week Low
$14.31
$0.37
52 Week High
$36.85
$2.09

Technical Indicators

Market Signals
Indicator
TSAT
LCTX
Relative Strength Index (RSI) 50.25 46.04
Support Level $28.65 $1.58
Resistance Level $31.00 $1.77
Average True Range (ATR) 2.16 0.08
MACD -0.14 -0.01
Stochastic Oscillator 21.63 32.65

Price Performance

Historical Comparison
TSAT
LCTX

About TSAT Telesat Corporation

Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: